Adicet Bio is a privately held, pre-clinical stage biotechnology company engaged in the design and development of cutting-edge immunotherapies with initial focus on cancer.
Adicet Bio focuses on the development of allogeneic cell therapies for cancer using innovative gamma delta T cells.
Adicet Bio was founded in late 2015 by Aya Jakobovits. The company is headquartered in Menlo Park, California, with an additional office in Haifa, Israel.
Adicet is developing novel universal immune cell therapies based on gamma delta T cells engineered with Chimeric Antigen Receptors (CARs) or T Cell Receptors (TCRs).
Adicet is also focused on identifying and validating cancer specific targets directed to the intracellular proteome and then generating T Cell Receptor-like monoclonal antibodies (TCRLs) directed to these cancer-specific peptide targets presented by MHC Class I complexes.
Adicet entered into a strategic collaboration with Regeneron Pharmaceuticals, in Aug 2016, to develop next-generation engineered immune-cell therapeutics using Adicet's gamma delta T cell allogeneic platform technology.
Adicet Bio is backed by OrbiMed, Novartis Venture Fund, RM Global Partners LLC, Pontifax, Moon2 Fund, Regeneron Pharmaceutical, JJDC and others. The company raised $80M from a "Series B" financing on Oct 2, 2019. The round brings Adicet's total funding to $145.63M to date.
Adicet Bio was recognized and named by FierceBiotech as a “Fierce 15” Biotech Company of 2016.